Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia
Standard
Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. / Stockschläder, M; Hegewisch-Becker, S; Krüger, W; tom Dieck, A; Mross, K; Hoffknecht, M; Berger, C; Kohlschütter, B; Martin, H; Peters, Stefan.
In: BONE MARROW TRANSPL, Vol. 16, No. 5, 11.1995, p. 663-7.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia
AU - Stockschläder, M
AU - Hegewisch-Becker, S
AU - Krüger, W
AU - tom Dieck, A
AU - Mross, K
AU - Hoffknecht, M
AU - Berger, C
AU - Kohlschütter, B
AU - Martin, H
AU - Peters, Stefan
PY - 1995/11
Y1 - 1995/11
N2 - The outcome of 14 bone marrow transplants (BMT) (autologous 4; allogeneic 10) for Philadelphia-chromosome (Ph1) positive acute lymphoblastic leukemia (ALL) was analyzed. Preparative regimens consisted of etoposide (VP16) (30 or 45 mg/kg BW) (n = 14), cyclophosphamide (CY)(120 mg/kg BW) (n = 14), and total body irradiation (TBI)(12 Gy) (n = 13) or busulfan (Bu)(16 mg/kg) (n = 1). All patients receiving autologous marrow were in complete remission (CR) (three patients in 1.CR, one patient in 2.CR) at the time of BMT. For allogeneic BMT (nine related, one unrelated donor), seven patients were in first CR, two patients in first refractory relapse, and one patient in second relapse. With a median follow-up of 503 days (range 93-1522 days), eight out of 14 patients are alive in remission (six out of 10 patients receiving allogeneic, and two out of four patients receiving autologous BMT). Disease-free survival for all patients is 46%. Causes of death were relapse (n = 3) and transplant-related toxicity (n = 3). All patients tested for the bcr/abl rearrangement by reverse transcriptase-polymerase chain reaction (RT-PCR) were negative 4 weeks post-BMT. Two of the three patients who subsequently relapsed were repeatedly RT-PCR positive prior to relapse (test not done in the third). Considering the negligible cure rate of Ph1-positive ALL with conventional chemotherapy regimens, our data support the concept of early (> or = 1 CR) BMT (allogeneic > autologous (purged) following triple therapy with TBI, VP16, and CY.
AB - The outcome of 14 bone marrow transplants (BMT) (autologous 4; allogeneic 10) for Philadelphia-chromosome (Ph1) positive acute lymphoblastic leukemia (ALL) was analyzed. Preparative regimens consisted of etoposide (VP16) (30 or 45 mg/kg BW) (n = 14), cyclophosphamide (CY)(120 mg/kg BW) (n = 14), and total body irradiation (TBI)(12 Gy) (n = 13) or busulfan (Bu)(16 mg/kg) (n = 1). All patients receiving autologous marrow were in complete remission (CR) (three patients in 1.CR, one patient in 2.CR) at the time of BMT. For allogeneic BMT (nine related, one unrelated donor), seven patients were in first CR, two patients in first refractory relapse, and one patient in second relapse. With a median follow-up of 503 days (range 93-1522 days), eight out of 14 patients are alive in remission (six out of 10 patients receiving allogeneic, and two out of four patients receiving autologous BMT). Disease-free survival for all patients is 46%. Causes of death were relapse (n = 3) and transplant-related toxicity (n = 3). All patients tested for the bcr/abl rearrangement by reverse transcriptase-polymerase chain reaction (RT-PCR) were negative 4 weeks post-BMT. Two of the three patients who subsequently relapsed were repeatedly RT-PCR positive prior to relapse (test not done in the third). Considering the negligible cure rate of Ph1-positive ALL with conventional chemotherapy regimens, our data support the concept of early (> or = 1 CR) BMT (allogeneic > autologous (purged) following triple therapy with TBI, VP16, and CY.
KW - Adult
KW - Aged
KW - Bone Marrow Transplantation/adverse effects
KW - Child
KW - Child, Preschool
KW - Female
KW - Fusion Proteins, bcr-abl/genetics
KW - Humans
KW - Hyperbilirubinemia/etiology
KW - Male
KW - Middle Aged
KW - Neoplasm, Residual
KW - Philadelphia Chromosome
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
KW - RNA, Messenger/analysis
KW - Survival Rate
M3 - SCORING: Journal article
C2 - 8547863
VL - 16
SP - 663
EP - 667
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 5
ER -